STK11 and lung adenocarcinoma: Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, et al. STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS- mutant lung adenocarcinoma.